Trial Profile
The comparison of efficacy and safety of continuing olanzapine to switching to quetiapine in overweight or obese patients with schizophrenia and schizoaffective disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Olanzapine (Primary) ; Quetiapine (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 18 Oct 2006 The expected completion date for this trial is now .
- 27 Mar 2006 New trial record.